Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells

7 Feb 2023

Abstract excerpt

Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by altered myeloid progenitor cell proliferation and differentiation. As in many other cancers, epigenetic transcriptional repressors such as histone deacetylases (HDACs) are dysregulated in AML. Here, we investigated (1) HDAC gene expression in AML patients and in different AML cell lines and (2) the effect of treating AML cells with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36831382
DOI: 10.3390/cancers15041039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML CellsPMID 36831382Read ↗

HDAC Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemiaSemantic proximity Read ↗

Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemiaSemantic proximity Read ↗

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated ApoptosisSemantic proximity Read ↗

Epigenetic-based differentiation therapy for Acute Myeloid LeukemiaSemantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemiaSemantic proximity Read ↗

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.